World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
106
Citations
50534
World Ranking
6433
National Ranking
3423

Joel M. Kremer publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where Joel M. Kremer sits on this spectrum.

101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 611 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101 publications 1,796+

This scientist: 480 publications — 54th percentile

54% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,796 publications or more.

Joel M. Kremer D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where Joel M. Kremer sits on this spectrum.

70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 400 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70 D-Index 217+

This scientist: 106 D-Index — 69th percentile

69% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 217 D-Index or more.

Overview

Joel M. Kremer is affiliated with Albany Medical Center Hospital in the United States. Their research is primarily situated within the field of Medicine, with a strong focus on Rheumatology, Genetics, Pathology and Forensic Medicine, Hematology, and Immunology. Over the course of their career, they have contributed to various subfields and topics reflecting a broad involvement in medical research.

The scientist's recent scholarly work includes significant publications such as:

  • 2021 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis (2021) in Arthritis Care & Research
  • 2021 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis (2021) in Arthritis & Rheumatology
  • Points to consider for the treatment of immune-mediated inflammatory diseases with Janus kinase inhibitors: a consensus statement (2020) in Annals of the Rheumatic Diseases
  • Incidence of venous and arterial thromboembolic events reported in the tofacitinib rheumatoid arthritis, psoriasis and psoriatic arthritis development programmes and from real-world data (2020) in Annals of the Rheumatic Diseases
  • Postapproval Comparative Safety Study of Tofacitinib and Biological Disease-Modifying Antirheumatic Drugs: 5-Year Results from a United States-Based Rheumatoid Arthritis Registry (2021) in ACR Open Rheumatology

The main topics Joel M. Kremer has worked on include:

  • Rheumatoid Arthritis Research and Therapies
  • Systemic Lupus Erythematosus Research
  • Chronic Lymphocytic Leukemia Research
  • Autoimmune and Inflammatory Disorders Research
  • Lymphoma Diagnosis and Treatment
  • Biosimilars and Bioanalytical Methods
  • Monoclonal and Polyclonal Antibodies Research

Frequent coauthors collaborating with Kremer include:

  • Dimitrios A. Pappas
  • George Reed
  • Jeffrey R. Curtis
  • Taylor Blachley
  • Kelechi Emeanuru

The venues where Joel M. Kremer often publishes are:

  • Annals of the Rheumatic Diseases
  • Rheumatology and Therapy
  • Arthritis Care & Research
  • Arthritis & Rheumatology
  • ACR Open Rheumatology

Joel M. Kremer's body of work demonstrates a focused engagement with autoimmunity and inflammatory disorders, particularly through clinical trials, safety studies of pharmaceuticals, and consensus guidelines within rheumatology. Their collaborative network includes multiple researchers active in related medical and therapeutic domains, contributing to peer-reviewed journals frequently accessed by specialists in these fields.

Best Publications

  • A trial of etanercept, a recombinant tumor necrosis factor receptor:Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate.

    Michael E. Weinblatt;Joel M. Kremer;Arthur D. Bankhurst;Ken J. Bulpitt

  • Genetics of rheumatoid arthritis contributes to biology and drug discovery

    Yukinori Okada;Yukinori Okada;Di Wu;Di Wu;Di Wu;Gosia Trynka;Gosia Trynka;Towfique Raj;Towfique Raj

  • 2012 Update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis

    Jasvinder A. Singh;Daniel E. Furst;Aseem Bharat;Jeffrey R. Curtis

  • Abatacept for rheumatoid arthritis refractory to tumor necrosis factor alpha inhibition.

    Mark C Genovese;Jean-Claude Becker;Michael Schiff;Michael Luggen

  • Treatment of rheumatoid arthritis by selective inhibition of T-cell activation with fusion protein CTLA4Ig.

    Joel M Kremer;Rene Westhovens;Marc Leon;Eduardo Di Giorgio

  • 2021 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis

    Liana Fraenkel;Joan M Bathon;Bryant R England;E William St Clair

  • Placebo-Controlled Trial of Tofacitinib Monotherapy in Rheumatoid Arthritis

    Roy Fleischmann;Joel Kremer;John Cush;Hendrik Schulze-Koops

  • Effects of abatacept in patients with methotrexate-resistant active rheumatoid arthritis: a randomized trial.

    Joel M. Kremer;Harry K. Genant;Larry W. Moreland;Anthony S. Russell

  • IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: results from a 24-week multicentre randomised placebo-controlled trial

    P Emery;E Keystone;H P Tony;A Cantagrel

  • Treatment of rheumatoid arthritis with anakinra, a recombinant human interleukin-1 receptor antagonist, in combination with methotrexate: results of a twenty-four-week, multicenter, randomized, double-blind, placebo-controlled trial.

    Stanley Cohen;Eric Hurd;John Cush;Michael Schiff

  • Methotrexate for rheumatoid arthritis. Suggested guidelines for monitoring liver toxicity. American College of Rheumatology

    J M Kremer;G S Alarcón;R W Lightfoot;R F Willkens

  • Dietary fish oil and olive oil supplementation in patients with rheumatoid arthritis. Clinical and immunologic effects.

    Joel M. Kremer;David A. Lawrence;William Jubiz;Ralph Digiacomo

  • The Safety and Efficacy of a JAK Inhibitor in Patients With Active Rheumatoid Arthritis Results of a Double-Blind, Placebo-Controlled Phase IIa Trial of Three Dosage Levels of CP-690,550 Versus Placebo

    Joel M. Kremer;Bradley J. Bloom;Ferdinand C. Breedveld;John H. Coombs

  • Fish-oil fatty acid supplementation in active rheumatoid arthritis. A double-blinded, controlled, crossover study.

    Joel M. Kremer;William Jubiz;Ann Michalek;Richard I. Rynes

  • Baricitinib in Patients with Refractory Rheumatoid Arthritis

    Mark C. Genovese;Joel Kremer;Omid Zamani;Charles Ludivico

  • Treatment of rheumatoid arthritis with the selective costimulation modulator abatacept - Twelve-month results of a phase IIb, double-blind, randomized, placebo-controlled trial

    Joel J.M. Kremer;Maxime Dougados;Paul Emery;Patrick Durez

  • Tofacitinib (CP‐690,550) in patients with rheumatoid arthritis receiving methotrexate: Twelve‐month data from a twenty‐four–month phase III randomized radiographic study

    Désirée van der Heijde;Yoshiya Tanaka;Roy Fleischmann;Edward Keystone

  • Tocilizumab Inhibits Structural Joint Damage in Rheumatoid Arthritis Patients With Inadequate Responses to Methotrexate: Results From the Double-Blind Treatment Phase of a Randomized Placebo-Controlled Trial of Tocilizumab Safety and Prevention of Structural Joint Damage at One Year

    Joel M. Kremer;Ricardo Blanco;Marek Brzosko;Ruben Burgos-Vargas

  • Concomitant leflunomide therapy in patients with active rheumatoid arthritis despite stable doses of methotrexate. A randomized, double-blind, placebo-controlled trial

    Joel M. Kremer;Mark C. Genovese;Grant W. Cannon;Jacques R. Caldwell

  • Fish-Oil Fatty Acid Supplementation in Active Rheumatoid Arthritis

    Joel M. Kremer;William Jubiz;Ann Michalek;Richard I. Rynes

Frequent Co-Authors

George W. Reed
George W. Reed University of Massachusetts Chan Medical School
Jeffrey R. Curtis
Jeffrey R. Curtis University of Alabama at Birmingham
Mark C. Genovese
Mark C. Genovese Stanford University
Michael E. Weinblatt
Michael E. Weinblatt Brigham and Women's Hospital
Paul Emery
Paul Emery University of Leeds
Daniel H. Solomon
Daniel H. Solomon Brigham and Women's Hospital
Roy Fleischmann
Roy Fleischmann The University of Texas Southwestern Medical Center
Daniel E. Furst
Daniel E. Furst University of California, Los Angeles
Maxime Dougados
Maxime Dougados Hôpital Cochin
Robert M. Plenge
Robert M. Plenge Bristol Myers Squibb

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Studying Medicine in the USA isn’t limited to pursuing a traditional MD. There are many alternative online degrees and career possibilities in the healthcare field, catering to different educational backgrounds and career goals.

For those already holding an RN license, pursuing the cheapest rn to bsn online programs offers a practical and cost-effective path to advance your nursing career. These programs combine affordability with quality and flexibility, meeting the needs of working professionals.

If you're a non-nurse seeking a rapid transition into advanced practice roles, consider exploring direct entry np programs for non nurses online. These innovative options accelerate your pathway to becoming a nurse practitioner, even if your undergraduate degree isn’t in nursing.

Entry barriers can also be a concern. To broaden your opportunities, research whats the easiest nursing program to get into? so you can find accessible programs that match your academic profile and support your aspirations.

Beyond nursing, roles in healthcare administration and support are in high demand. Consider enrolling in online medical coding classes with financial aid to quickly gain valuable technical skills that open doors to remote and in-person healthcare settings.

Best Scientists Citing Joel M. Kremer

Trending Scientists

Recently Published Articles